Harmony Biosciences Reports Positive Bioequivalence Results for Pitolisant GR Formulation, Plans 2026 NDA Submission
Key Insights
Harmony Biosciences announced positive pivotal bioequivalence study results showing 17.8 mg pitolisant GR (search) is bioequivalent to the currently marketed 17.8 mg pitolisant tablet.
Dosing-optimization study results demonstrated all patients could start treatment directly at the therapeutic 17.8 mg dose, eliminating the need for dose titration.
The company remains on track to submit a new drug application for pitolisant GR (search) in early 2026, with a targeted PDUFA date in the first quarter of 2027.
Harmony Biosciences Holdings (search) announced positive pivotal bioequivalence study results for its new pitolisant gastro-resistant (GR) formulation, marking a significant milestone in the company's efforts to extend its leadership position in sleep disorder therapeutics. The study demonstrated that 17.8 mg of pitolisant GR (search) is bioequivalent to the currently marketed 17.8 mg pitolisant tablet, setting the stage for a planned New Drug Application submission in early 2026.
Study Results and Clinical Implications
The bioequivalence study results provide critical data supporting the development of the new gastro-resistant formulation of pitolisant, which is currently marketed as Wakix for the treatment of narcolepsy (search). Alongside the bioequivalence findings, topline results from a dosing-optimization study showed that all patients were able to start treatment directly at the therapeutic 17.8 mg dose, removing the need for dose titration.
This dosing optimization represents a potential clinical advantage, as it could simplify treatment initiation and improve patient compliance by eliminating the traditional titration period required with the current formulation.
Regulatory Timeline and Market Impact
With positive results from both studies, Harmony Biosciences remains on track to submit a new drug application for pitolisant GR (search) in early 2026, with a targeted Prescription Drug User Fee Act (PDUFA) date in the first quarter of 2027. This regulatory timeline positions the company to potentially launch the new formulation within the next few years.
The successful bioequivalence study meaningfully strengthens the upcoming NDA submission and offers a strong near-term catalyst that directly addresses the core risk of product concentration for Harmony Biosciences, which currently depends heavily on WAKIX revenue.
Patent Protection and Competitive Positioning
Patent applications for the new formulation could potentially extend pitolisant exclusivity to 2044, providing substantial long-term protection for Harmony's core asset. This extended patent protection is particularly significant as it could help the company manage upcoming competitive pressures and generic threats while maintaining its market position in sleep disorder therapeutics.
The company's narrative projects $1.2 billion in revenue and $333.5 million in earnings by 2028, requiring 17.0% yearly revenue growth and a $152.6 million increase in earnings from the current $180.9 million. The successful development of the GR formulation supports this growth trajectory by potentially extending the commercial life of pitolisant.
Market Response
Following the announcement, Harmony Biosciences shares were up 0.32% in pre-market trading at $34.42, reflecting investor confidence in the positive study results and their implications for the company's future prospects in the sleep disorder therapeutics market.